Tick-derived amblyommin and method of antithrombin therapy

Details Tick-derived amblyommin and method of antithrombin therapy Tick-derived amblyommin and method of antithrombin therapy

1989-06-02

1992-03-03

Lacey, David L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

530350, 530381, 530855, 514 12, C07K 1500, A61K 3764

Patent

active

050933221

ABSTRACT:
The invention relates to a new active substance--amblyommin--for anticoagulant therapy and to a process for the isolation thereof from hard ticks. The isolated protein having a thrombin-inhibitory action has a molecular weight of 20000 to 30000 dalton, an isoelectric point between 5.05 and 5.65 and the partial amino acid sequences

REFERENCES:
patent: 4668662 (1987-05-01), Tripier
P. Willadsen et al., Biochem. J., 189: 295-303, (1980).
J. Ribeiro et al., J. Exp. Med., vol. 161, pp. 332-344, (Feb. 1985).
K. Hellmann et al., Thrombosis Diath. Haemorrh., vol. 18, pp. 617-625, (1967).
Nieuwenhuizen & Gravesen, Biochimica Biophysica Acta, 668(1981) 81-88.

Affiliated with

Also associated with

Rating

Tick-derived amblyommin and method of antithrombin therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tick-derived amblyommin and method of antithrombin therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tick-derived amblyommin and method of antithrombin therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-272258